Posted by Michael Wonder on 01 May 2020
The global imperative to make cancer medications affordable
1 May 2020 - The value of any medication is determined by the magnitude of the clinical benefit (improved survival and quality of life of patients) and the cost of the medication.
Recent studies have suggested that, in the USA, there is no correlation between value and list prices for new cancer medicines.
Assuming that this disparity is an aberration caused by the suspension of market forces in cancer medication pricing in the USA, it seemed reasonable to hypothesise that the situation might be different in countries with robust processes for health technology assessment and managed market entry with price negotiation.
